Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.84 |
| ▸ | FNTB | P49356 | 9/20 | 0.84 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11954821 | 0.93 | FNTA (0.71) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL13573622 | 0.92 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL1682772 | 0.92 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL13928075 | 0.92 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL11954235 | 0.91 | FNTA (0.69) | FNTAFNTBPGGT1BCYP3A4 | |
| Hydrochloric Acid SCHEMBL6435591 | 0.91 | FNTA (0.98) | FNTAFNTBCYP3A4 | |
| SCHEMBL6010387 | 0.91 | FNTA (0.91) | FNTAFNTBCYP3A4 | |
| SCHEMBL5654543 | 0.90 | FNTA (0.96) | FNTAFNTBCYP3A4 | |
| SCHEMBL5659780 | 0.90 | FNTA (0.80) | FNTAFNTBCYP3A4 | |
| SCHEMBL11954234 | 0.89 | FNTA (0.67) | FNTAFNTBPGGT1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | JANSSEN-CILAG S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1322636-A1 | FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024683-A1 | FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | FNTB, FNTA, CYP7A1 | FNTA 2/4885FNTB 1/4885PGGT1B 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.